SNX-5422

DRUG10 trials

Sponsors

Esanex Inc., National Cancer Institute (NCI)

Conditions

CancerHematologic NeoplasmsLymphomaNeoplasms

Phase 1

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

CompletedNCT00506805

Esanex Inc.Cancer

Start: 2007-06-30End: 2010-03-31Updated: 2012-05-28

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

CompletedNCT00595686

Esanex Inc.Hematologic Neoplasms

Start: 2008-01-31End: 2010-05-31Updated: 2012-05-17

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

CompletedNCT00644072

National Cancer Institute (NCI)Lymphoma, Neoplasms

Start: 2008-03-07End: 2011-06-16Updated: 2017-07-02

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies

CompletedNCT01611623

Esanex Inc.Cancer

Start: 2012-05-31End: 2013-03-31Updated: 2013-04-02

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

CompletedNCT01635712

Esanex Inc.Cancer

Start: 2014-02-28End: 2017-02-28Updated: 2017-04-26

Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

TerminatedNCT01848756

Esanex Inc.Cancer

Start: 2013-04-30End: 2015-06-30Updated: 2017-02-09

Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma

CompletedNCT01851096

Esanex Inc.Cancer

Start: 2013-03-31End: 2016-08-31Updated: 2016-08-16

Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors

CompletedNCT01892046

Esanex Inc.Cancer

Start: 2013-11-30End: 2017-07-31Updated: 2017-07-26

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

CompletedNCT02063958

Esanex Inc.Cancer

Start: 2014-02-28End: 2018-03-20Updated: 2018-07-30

Phase 2

Study of SNX-5422 in TP53 Null Cancers

TerminatedNCT02612285

Esanex Inc.Cancer

Start: 2016-03-31End: 2016-10-31Updated: 2018-11-14

Related Papers

A phase 1B study of SNX-5422 plus carboplatin (C) and paclitaxel (P) in patients with advanced non-small-cell lung cancer (NSCLC).

Journal of Clinical Oncology2017-05-201 citations

A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers.

Journal of Clinical Oncology2015-05-20